News
Updates on activities and accomplishments at AYOXXA
As a young and dynamic company determined to anticipate and respond to customer needs, we continue to achieve milestones, bring novel products to market, expand our partnerships, and explore use of our LUNARIS™ technology in new research areas. Follow these developments here.
Coronavirus Update
Conferences
Meet AYOXXA
AYOXXA @ 14th Annual Biomarkers Congress 2019 in Manchester
AYOXXA introduces its innovative LUNARIS™ technology to senior level attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions, all working in the biomarker space across multiple therapeutic areas worldwide.
Read more
Meet AYOXXA
AYOXXA @ 37th Annual J.P. Morgan Healthcare Conference
AYOXXA introduces its innovative LUNARIS™ platform to executives from internationally renowned pharmaceutical and biotech companies as well as to members of the investment community, meeting at the largest and most informative healthcare investment symposium in the industry from January 7 - 10, 2019 at the Westin St. Francis Hotel in San Francisco, California.
Read more
Meet AYOXXA
AYOXXA @ the "iSearch", Basic Research in Ophthalmology Meeting
iSearch is a forum for basic experimental research in ophthalmology, where new findings about signaling pathways and pathomechanisms involving immune cells of the retina are presented.
Read more
Meet AYOXXA
AYOXXA @ the 6th Annual Meeting of the International Cytokine & Interferon Society in Boston
AYOXXA will be at the epicenter of cytokine and interferon research to exhibit the LUNARIS™ platform with its growing portfolio of multiplex cytokine detection kits, and to discuss its unique advantages for basic and translational applications.
Read more
Meet AYOXXA
AYOXXA @ 3rd Annual Biomarkers Congress, San Diego
AYOXXA introduces its innovative LUNARIS™ platform to executives from internationally renowned pharmaceutical and biotech companies as well as to leading scientists from academic and government institutions, meeting in one of the most vibrant life science clusters in Southern California.
Read more
Meet AYOXXA
AYOXXA @ ECI 2018 in Amsterdam
AYOXXA will present its proprietary LUNARIS™ platform technology and growing portfolio of bead-based immunoassay detection kits at the 5th European Congress of Immunology.
Read morePress Reviews
Press Review
Meet Rodney Turner, CEO of Multiplex Protein Analysis Company AYOXXA
BIO-Europe offers many opportunities. One of them is meeting with companies’ representatives to have a chat. In this context, we met with Rodney Turner, CEO of German company AYOXXA, which markets a technology for multiplex protein analysis. Although it may sound complicated, the technology is quite straightforward. Simply put, it is the parallel analysis of multiple proteins from one single, very small sample.
Read more
Press Review
Meet Rodney Turner, CEO of Multiplex Protein Analysis Company AYOXXA
BIO-Europe offers many opportunities. One of them is meeting with companies’ representatives to have a chat. In this context, we met with Rodney Turner, CEO of German company AYOXXA, which markets a technology for multiplex protein analysis. Although it may sound complicated, the technology is quite straightforward. Simply put, it is the parallel analysis of multiple proteins from one single, very small sample.
Read more
Press Review
Beads-on-a-Chip-Multiplex-System: Analyse kleinster Volumina (Laborpraxis)
Ayoxxa Biosystems präsentiert mit Lunaris ein Bead-basiertes Multiplex-System zur Analyse kleinster Proteinprobenvolumina.
Read more
Press Review
AYOXXA launches new beads-on-a-chip multiplex protein
AYOXXA Biosystems (Cologne, Germany) have introduced a novel system, termed LUNARIS™, which is aimed to quantify soluble inflammation and immune response markers...
Read morePress Releases
Press Release
AYOXXA launches LUNARIS™ Human 11-Plex Ophthalmology Kit
For multiplexed analysis of biomarker signatures in ocular fluids including vitreous and aqueous samples. Covering: angiogenic & inflammatory factors, chemokines known to be relevant in the pathology of retinal angiogenic diseases next to VEGF, the target molecule of today’s standard of care.
Read more
Press Release
AYOXXA develops multiplex assay for stratification of sepsis patients using soluble biomarkers
AYOXXA Biosystems GmbH joined "SepsisDataNet.NRW" research project funded by EFRE and comprises a consortium of NRW companies, university hospitals and universities. Funding started in July 2017 for a period of three years.
Read more
Press Release
AYOXXA launches LUNARIS Mouse 12-Plex Th17 Kit to elucidate Th17 cell biology
LUNARIS™ Mouse 12-Plex Th17 Kit comprises highly specific reagents for the quantitative analysis of soluble markers of Th17 cell biology Kit includes the primary Th17 related cytokines involved in autoimmune disorders, immune-mediated diseases as well as asthma, allergy, cancer, microbial defense and transplantation Launch marks a further step in establishing AYOXXA’s LUNARIS™ as the technology of choice for fully scalable beads-on-a-chip multipl
Read more
Press Release
AYOXXA introduces LUNARIS™, its advanced fully integrated low-volume beads-on-a-chip multiplex protein analysis system
AYOXXA Biosystems GmbH, an international biotechnology company, today announces the introduction of its advanced low-volume beads-on-a-chip multiplex protein analysis system. The LUNARIS™ system can be readily integrated into any laboratory routine and is optimized to provide easy-to-use, standardized workflow from sample to result.
Read more
Press Release
AYOXXA is Member of the International EYE-RISK Consortium
Cologne 22 October 2015 - AYOXXA Biosystems GmbH, an international biotechnology company, is one of two industrial partners of EYE-RISK, a large biomedical consortium bringing together the expertise of ten renown scientific and clinical institutions and a patient organization from six European countries. It is led by Prof. Dr.
Read more
Press Release
Collaboration between AYOXXA and the Singapore Eye Research Institute
Singapore 2 March 2015 - AYOXXA, an international biotech company with headquarters in Cologne, has signed an agreement with the Singapore Eye Research Institute (SERI), one of the leading international eye research institutes. AYOXXA and SERI will work together on validating the company’s multiplexing technology platform for protein biomarker detection, as part of an expanded collaboration for developing ophthalmic diagnostic tools.
Read more